Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03583086 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | completed | Phase 1 / Phase 2 | 88 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT01306045 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | completed | Phase 2 | 647 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2024 |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT04852679 | Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs(PALACE) | completed | Phase 3 | 43 | IpsenINDUSTRY | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04768296 | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | completed | Phase 2 | 76 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 7 | Sep 26, 2024 | clinicaltrials |
| NCT01678664 | Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors(EVACEL) | completed | Phase 2 | 74 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04160065 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers | completed | Phase 1 | 23 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Sep 23, 2024 | clinicaltrials |
| NCT00686985 | Docetaxel - Carboplatin As Second Line Treatment in Patients with Small Cell Lung Cancer(DOCAR) | completed | Phase 2 | 50 | Dr. B. BiesmaOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT01379898 | Phenoxybenzamine Versus Doxazosin in PCC Patients(PRESCRIPT) | completed | Phase 4 | 134 | University Medical Center GroningenOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04434482 | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 59 | Impact Therapeutics, Inc.INDUSTRY | 5 | Sep 19, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT02815592 | Trial of BMS-986012 in Combination With Platinum and Etoposide | completed | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 4, 2024 | clinicaltrials |
| NCT06570174 | Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients | completed | N/A | 60 | Yonsei UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT05053685 | Metanephrines in Obstructive Sleep Apnoea | completed | — | 81 | Changi General HospitalOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06550518 | Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study.(EPITAX) | completed | — | 29 | University Hospital, BrestOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06526481 | Nasoseptal Double Flap Versus Rescue Flap in Endoscopic Transsphenoidal Pituitary Surgery | completed | N/A | 56 | Mansoura UniversityOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT03417895 | SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy(PASSION) | completed | Phase 2 | 59 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT01357395 | A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer(ESCAPE) | completed | Phase 2 | 23 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT04622228 | Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer(Match) | completed | Phase 2 | 56 | Hoffmann-La RocheINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT02923934 | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | completed | Phase 2 | 120 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04854590 | IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer | completed | — | 248 | AstraZenecaINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT01873248 | Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective | completed | Early Phase 1 | 100 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT04028050 | A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(MAURIS) | completed | Phase 3 | 155 | Hoffmann-La RocheINDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05371899 | Mass Balance Study of [14C]Chiauranib | completed | N/A | 6 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT04727853 | Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 66 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04902885 | Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients | completed | Phase 3 | 95 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT01856920 | QUILT-3.006 for Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 35 | NantCell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04730999 | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer(CeLEBrATE) | completed | Phase 2 | 54 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT02978404 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | completed | Phase 2 | 26 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT01556230 | Prospective Study of Clinically Nonfunctioning Pituitary Adenomas(PAPS) | completed | — | 292 | Columbia UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT02200757 | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | completed | Phase 2 | 135 | ImmunityBio, Inc.INDUSTRY | 3 | Jun 25, 2024 | clinicaltrials |
| NCT03288402 | Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients(DIB-NET) | completed | N/A | 346 | University Hospitals Coventry and Warwickshire NHS TrustOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04860700 | The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma | completed | Phase 2 | 27 | Peking Union Medical College HospitalOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03038308 | Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole | completed | Phase 1 / Phase 2 | 16 | Columbia UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05116007 | Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC | completed | Phase 1 | 35 | AkesoINDUSTRY | 1 | May 31, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT05236829 | Exercise Capacity and Physical Activity Level in Prolactinoma Patients | completed | — | 38 | Hacettepe UniversityOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT04079595 | Closed vs. Open Face Masks for Cranial Radiotherapy | completed | N/A | 60 | University of ZurichOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT02164461 | Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer | completed | Phase 1 | 12 | Advaxis, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT01941316 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 78 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | May 9, 2024 | clinicaltrials |
| NCT04324437 | eRAPID: Online Symptom Reporting in Lung Cancer | completed | N/A | 43 | University of LeedsOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04393753 | Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1(MERKLIN2) | completed | Phase 2 | 19 | 4SC AGINDUSTRY | 6 | May 8, 2024 | clinicaltrials |
| NCT05253144 | Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC(Rational-MCC) | completed | N/A | 64 | University of BirminghamOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT00970970 | Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease(VHLimage) | completed | — | 22 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01398306 | Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.(BANN) | completed | — | 40 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01849523 | Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study(WIN) | completed | N/A | 20 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 8, 2024source: clinicaltrials